Education
About Us
Working with TipRanks
Follow Us
Akari Therapeutics (AKTX)
NASDAQ:AKTX
AKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $4.40
Previous CloseN/A
Volume16.29K
Average Volume (3M)13.90K
Market Cap
$35.58M
Enterprise Value-$714.28K
Total Cash (Recent Filing)$2.58M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,176,370
10 Day Avg. Volume13,403
30 Day Avg. Volume13,897
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Akari Therapeutics News
PremiumCompany Announcements
Akari Therapeutics Reports Q1 2025 Financial Results
PremiumCompany Announcements
Akari Therapeutics Advances ADC Development Amid Financial Challenges
PremiumCompany Announcements
Akari Therapeutics Delays Yearly Financial ReportOptions Prices
Currently, No data available
---
Ownership Overview
36.07% Insiders
0.76% Other Institutional Investors
63.17% Public Companies and
Individual Investors
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $0.85 and its highest was $4.40 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $35.58M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Sep 25, 2025 which is in 108 days.
How were Akari Therapeutics’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Overvalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 32,176,370 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
Akari Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.74%
12-Months-Change
Fundamentals
Return on Equity
-197.11%
Trailing 12-Months
Asset Growth
1738.35%
Trailing 12-Months
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
AKTX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
X4 Pharmaceuticals
―
Lantern Pharma
―
Shattuck Labs
―
Coeptis Therapeutics Holdings
―
LAVA Therapeutics
―